Jazz Pharmaceuticals plc 4

Non-employee director Mark Douglas Smith received an award of 1,605 restricted stock units of Jazz Pharmaceuticals plc on August 5, 2026.

On August 5, 2026, Mark Douglas Smith, a non-employee director of Jazz Pharmaceuticals plc, received a grant of 1,605 restricted stock units (RSUs) representing ordinary shares under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan. The RSUs carry no purchase price and will vest in full on July 23, 2027, subject to his continued service and specified conditions. Following this equity award, Smith’s direct holdings in Jazz Pharmaceuticals increased to 11,285 ordinary shares (including the newly granted RSUs), reflecting a routine director compensation grant rather than an open-market transaction.

Filing Facts

CIK

1232524

Ticker

JAZZ

Form

4

Source Type

fda

Accession

0001756253-26-000006

Alert Tier

5